Clinical Trials Logo

Neoplasms by Site clinical trials

View clinical trials related to Neoplasms by Site.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06376084 Not yet recruiting - Neoplasms Clinical Trials

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

FOREFRONT
Start date: July 24, 2024
Phase:
Study type: Observational

To estimate parameters related to clinical outcomes in a real-world seeting, including investigator reported PFS and OS.

NCT ID: NCT04807166 Not yet recruiting - Ovarian Neoplasms Clinical Trials

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

It has been reported that antiangiogenic drugs combined with chemotherapy as first-line treatment, and subsequent antiangiogenic drugs as maintenance therapy for ovarian cancer can achieve better clinical benefits. Therefore, this study is expected to investigate the efficacy and safety of anlotinib combined with carboplatin/paclitaxel as first-line treatment in patients with advanced ovarian cancer.

NCT ID: NCT01556815 Not yet recruiting - Liver Diseases Clinical Trials

Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma

Start date: May 2012
Phase: Phase 2
Study type: Interventional

Transarterial chemoembolization (TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the hypoxia caused by TACE in surviving tumor cell leads to release of angiogenic and growth factors contributing to poor outcome. Sorafenib can block tumor cell proliferation and angiogenesis. The hypothesis is that patients with unresectable HCC may benefit from sorafenib in combination with TACE.